Veracyte Inc logo

VCYT - Veracyte Inc News Story

$46.91 -8.5  -15.3%

Last Trade - 04/03/21

Sector
Healthcare
Size
Mid Cap
Market Cap £2.26bn
Enterprise Value £2.01bn
Revenue £84.6m
Position in Universe 1752nd / 6647

BRIEF-Veracyte Reports New Data Reinforcing Foundational Technology Of Nasal Swab Test For Early Lung Cancer Detection

Mon 19th October, 2020 1:17pm
Oct 19 (Reuters) - Veracyte Inc  VCYT.O :
    * VERACYTE ANNOUNCES NEW DATA REINFORCING FOUNDATIONAL
TECHNOLOGY
OF NASAL SWAB TEST FOR EARLY LUNG CANCER DETECTION PRESENTED AT
CHEST ANNUAL MEETING 2020
    * VERACYTE INC - PLANS TO UNVEIL EARLY DATA FOR NASAL SWAB
TEST
BEFORE END OF 2020
    * VERACYTE INC - PLANS TO INTRODUCE TEST IN UNITED STATES IN
SECOND HALF OF 2021

Source text for Eikon:  ID:nBw2Wkf3Va 
Further company coverage:  VCYT.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.